

TOP 5 BIOTECH STOCKS

THAT COULD DOUBLE IN 2021



The Top 5 Biotech Stocks That Could Double in 2021

Biotech is still one of the most exciting sectors to invest in.

By 2025, the global biotech market could be worth up to \$720 billion, according to Global Market Insights. In fact, they note:

“An increasing number of chronic diseases including cancer, heart disease, stroke, asthma, chronic respiratory diseases and hypertension among others will positively influence the biotechnology market growth. Unhealthy diet and lifestyle habits including alcohol consumption and tobacco are among the major reasons for the increase in the prevalence of chronic diseases. Therefore, the Department of Biotechnology through technical expert committee (TEC) and expert groups are focusing on R&D activities to develop innovative methods in cancer and neuro-disease biology. Hence, rising incidences of such chronic diseases, owing to several factors including stress and sedentary lifestyles, foster the overall business growth.”

Two, the sector is still one of the safest, most recession-proof investment around. We can't stop folks from aging, or from needing treatments for a large range of medical issues.

Three, an aging population is demanding more treatments in an effort to live longer lives. At the moment, there are 65 million people over the age of 70 in the United States. As this number continues to grow, we'll see a need for more medication and treatment options.

There's also incredible new innovation in genetics and technology, creating new life-saving and life enhancing opportunities. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls created by patent expirations.

With that in mind, here are five of the top biotech stocks to consider right now.

Biotech Opportunity No. 1 – Ocugen Inc. (OCGN)

Since December 2020, the OCGN stock exploded from a low of 29 cents to \$8.74.

All on news it's working on a CV-19 vaccine with Bharat Biotech, and on news the treatment had an efficacy rate of 81%.



"Today's results from the interim analysis of Bharat Biotech's Phase 3 trial of COVAXIN mark a milestone in the development of another critical vaccine option for the US market. COVAXIN has been shown to induce immune responses against multiple protein antigens of the virus potentially reducing the possibility of mutant virus escape."

Should the company provide further positive news on the CV-19 vaccine, we believe the stock could double, if not triple this year. Analysts are just as bullish. In fact, HC Wainwright just noted that, "Compared to COVID-19 vaccines currently authorized under EUA, COVAXIN could induce more broad immunity targeting multiple viral proteins, potentially resulting in better protection against emerging mutant viruses, such as the UK and South African variants."

Biotech Opportunity No. 2 – AVEO Pharmaceuticals (AVEO)

AVEO is another hot biotech stock to consider.



At the moment, we're waiting on a US FDA decision on the company's Tivozanib for the treatment of advanced renal cell carcinoma. In fact, there's a March 31 PDUFA date nearing following positive results from a late-stage study.

According to a Feb. 2021 press release, "Data reported today continue to support tivozanib's differentiation among TKIs and its potential to serve as a meaningful option for RCC patients who have relapsed or become refractory to multiple lines of therapy," said Brian Rini, MD, Chief of Clinical Trials at Vanderbilt Ingram Cancer Center. "Of note, sequencing data suggest differential activity between tivozanib and axitinib, despite both being potent and selective VEGF TKIs. With no existing evidence-based standard of care for this historically difficult-to-treat population, tivozanib could potentially play a key role in the evolving relapsed or refractory RCC treatment landscape."

With that, analysts at Baird have a Buy rating with a price target of \$17 a share.

Biotech Opportunity No. 3 – TG Therapeutics (TGTX)

Shares of TGTX have been just as explosive running from \$5 to \$45.

However, the push higher may have only begun.



Michael S. Weiss, the Executive Chairman and Chief Executive Officer, stated, "2020 was a year of data and regulatory execution for us as we delivered results from our UNITY-NHL study that led to the approval of UKONIQ in relapsed/refractory MZL and FL and from UNITY-CLL that will be used to support the current rolling BLA submission for ublituximab in combination with umbralisib for patients with CLL," as quoted in a company press release.

"We also announced the top line results from our ULTIMATE MS Phase 3 trials that will be used to support a BLA submission for ublituximab in MS. These successful outcomes were made possible by the hard work of everyone at TG over many years and has positioned us for an exciting 2021." Mr. Weiss continued, "With the UKONIQ launch underway, we are excited to keep the momentum going and expect this year to complete our BLA submission for U2 in CLL, present final results from the ULTIMATE trials and then submit a BLA for ublituximab in MS, and continue to advance our triple therapy combination trials and our early pipeline."

Biotech Opportunity No. 4 – Editas Medicine (EDIT)

Gene editing stocks like EDIT have become ridiculously oversold.

The company has two key clinical studies. At the moment, it's dosing patients in an early stage study of EDIT-101 Leber congenital amaurosis type 10, a rare genetic eye disease. It has also initiated a Phase 1/2 study for EDIT-301 for sickle cell disease. Helping, CEO James C. Mullen just bought 25,000 shares of EDIT in March 2021 at an average price of \$46.27 a share. The total cost was about \$1.2 million.



In its latest press release, the company announced the following:

- **EDIT-101 for Leber Congenital Amaurosis 10 (LCA10)**
Dosed first patient in the adult mid-dose cohort of the BRILLIANCE trial
Editas Medicine has dosed the first patient of the second cohort, the adult mid-dose, with EDIT-101. Initial clinical data is expected in 2021.

- **Retinitis Pigmentosa Type 4**

On track for development candidate by end of 2021

Editas Medicine is on-track to declare a development candidate for the treatment of Retinitis Pigmentosa Type 4 (adRP4) by the end of 2021. The Company plans to present preclinical data at a scientific meeting later this year.

- **EDIT-301 for Sickle Cell Disease**

Initiation of Phase 1/2 RUBY trial

The U.S. Food and Drug Administration (FDA) has approved the start of the Phase 1/2 RUBY study for sickle cell disease, and the Company can begin enrolling patients.

- **Edited iPSC NK (iNK) Cell Medicines to Treat Solid Tumors**

Proprietary CRISPR/Cas12a editing of iPSCs enhances iNK tumor killing for potential off-the-shelf medicine -- Preclinical data presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH) highlighted the Company's CRISPR/Cas12a induced pluripotent stem cell (iPSC) editing platform.

Biotech Opportunity No. 5 – Cassava Sciences (SAVA)

While SAVA already ran from \$10 to \$43, there could be further upside here. In fact, analysts at Maxim have a price target of \$80, noting, “The space is shifting, and SAVA's simufilam is about as advanced as any asset in this new wave of AD therapeutics.”



Analysts at HC Wainwright have a target of \$97 with a buy rating.

Most recently, the company posted positive results on Simufilam, and its ability to improve cognition and behavior in Alzheimer's disease in an interim study. “We could not be more pleased with these interim results,” said Remi Barbier, President & CEO, as quoted in a company press release. “We would have been satisfied to show simufilam stabilizes cognition in patients over 6 months. An improvement in cognition and behavior tells us this drug candidate has potential to provide lasting treatment effects for people living with Alzheimer's disease. It's an exciting development.”

As the company moves towards Phase 3 trials, we expect to see further upside in SAVA.

DISCLAIMER:

This manual is for informational and entertainment purposes only. The author is not an investment adviser, financial adviser, or broker, and the material contained herein is not intended as investment advice. If you wish to obtain personalized investment advice, you should consult with a Certified Financial Planner (CFP). All statements made in this manual are based on the author's own opinion. Neither the author or the publisher warrants or assume any responsibility for the accuracy of the statements or information contained in this manual, and specifically disclaims the accuracy of any data, including stock prices and stock performance histories. No mention of a particular security or instrument herein constitutes a recommendation to buy or sell that or any security or instrument, nor does it mean that any particular security, instrument, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Neither the author or the publisher, can assess, verify, or guarantee the accuracy, adequacy, or completeness of any information, the suitability or profitability of any particular investment or methodology, or the potential value of any investment or informational source. READERS BEAR THE SOLE RESPONSIBILITY FOR THEIR OWN INVESTMENT DECISIONS. NEITHER THE AUTHOR OR THE PUBLISHER IS RESPONSIBLE FOR ANY LOSSES DUE TO INVESTMENT DECISIONS MADE BASED ON INFORMATION PROVIDED HEREIN. At the time of writing, neither the author or the publisher has a position in any of the stocks mentioned in this manual. By proceeding with reading this course, you affirm that you have read and understand the above disclaimer.